Navigation Links
Sofie Biosciences receives $1M Phase II SBIR grant from the DOE
Date:7/11/2012

CULVER CITY, Calif., July 11, 2012 /PRNewswire/ -- Sofie Biosciences, Inc., a molecular imaging company offering a comprehensive range of products from preclinical imaging systems to novel diagnostic PET imaging probes, announced today that the Department of Energy has awarded the company a grant under the Small Business Innovation Research (SBIR) program. This Phase II award, for approximately $1M, will support the development of a microscale technology for rapid, easy synthesis of PET probes.

(Logo: http://photos.prnewswire.com/prnh/20101208/LA13841LOGO)

Presently, scientists and clinicians must accept the limitations of the centralized radiopharmacy model of PET probe production and distribution, where a limited number of probes are available from radiochemistry cores or, more often, commercial radiopharmacies that provide an even smaller menu from which to choose. The end result is that the average investigator is restricted to a handful of PET probes, namely [18F]FDG, [18F]NaF, and occasionally [18F]FLT, leaving the 1,600+ probes that have been synthesized just out of reach, thus drastically limiting the translational power of PET to a few disciplines and applications.

"We are extremely pleased to be recognized with this highly competitive award from DOE," said Patrick W. Phelps, President and CEO. "It's an important step to further the development of a proprietary, game-changing technology that will provides researchers and clinicians with a first-generation device for the production of one-pot PET probes."

These funds will be invested alongside Sofie resources to help broaden access to novel PET probes to answer fundamental biological questions in disease. "Winning this grant from DOE both supports and accelerates our efforts to bring radiochemistry-on-chip to market, a critical step in Sofie's vision of creating a transformative technology of an affordable, compact, easy-to-use system for the on-demand production of PET probes," commented Dr. Melissa Esterby, Director, Technology Development, who will be the Principal Investigator working in close collaboration with co-PI and inventor Dr. R. Michael van Dam at UCLA.

About Sofie Biosciences

Sofie is combining new PET imaging agents with innovative imaging systems to provide researchers and physicians with technologies to better investigate the biology of disease. By empowering a wide array of people with valuable, translational imaging tools, Sofie is making PET scans more accessible and increasing the diversity of its applications.  For more information on Sofie, contact Dr. Jennifer Cho at +1 424.223.6948 or jennifer.cho@sofiebio.com.


'/>"/>
SOURCE Sofie Biosciences
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. 3-V Biosciences To Present at the Seventh Annual JMP Securities Healthcare Conference
2. Neurocrine Biosciences to Present at the Jefferies 2012 Global Healthcare Conference
3. Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor
4. Pressure BioSciences, Inc. to Discuss First Quarter 2012 Financial Results And Provide Business Update
5. Neurocrine Biosciences Reports First Quarter 2012 Results
6. Amarantus BioSciences to Present at the New York Biotechnology Association (NYBA) 21st Annual Meeting on May 2nd, 2012
7. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results
8. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
9. Asthmapolis Receives FDA Clearance for Asthma Inhaler Sensor Technology and Accompanying Software System
10. Integrity Life Sciences Receives US FDA 510(k) Clearance for its Integrity Spinal Care System Medical Device
11. AtheroNova Receives Notice of Allowance for Its US Patent Application 12/024,908
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2019)... ... December 13, 2019 , ... ... Rights of the Child (ARC) ( http://www.arclaw.org ) has today criticized a ... Africa, though only on boys mostly 15 years of age and older. ...
(Date:12/9/2019)... ... December 09, 2019 , ... American ... throughout North America has released its documentary on " Making Data Work: Leveraging ... how pharmaceutical companies are currently using data to produce products, and how they ...
(Date:12/8/2019)... ... December 07, 2019 , ... Soterius, Inc., an outsourced service ... announced that MAIA Pharmaceuticals, Inc. (MAIA), a specialty pharmaceutical company focused on development ... partners in Europe, to support their regulatory strategy and operations for filings in ...
Breaking Medicine Technology:
(Date:12/6/2019)... ... December 06, 2019 , ... C&A ... excellence in employee learning. The Omaha-based company has been named by Training magazine ... successful employer-sponsored training and development programs worldwide. Rankings of the 125 leading companies ...
(Date:12/6/2019)... SALT LAKE CITY (PRWEB) , ... December 06, ... ... “bravery” and “gratitude” were used frequently, six students in Salt Lake Community ... Hanscom, Hevelyn Cidade Klegues, Mark Rodgers and Chelise Schaefer—were awarded the AT&T Public ...
(Date:12/6/2019)... ... 06, 2019 , ... COMPLIANCY GROUP is proud to announce ... Society. Compliancy Group is dedicated to educating and assisting Wyoming Medical Society’s members ... the standards set forth by the Health Insurance Portability and Accountability Act (HIPAA). ...
(Date:12/6/2019)... ... ... Dr. Scott Howell, a 2019 graduate of Trident University International’s (Trident) ... coconut oil in the 7 November 2019 edition of Progress in Cardiovascular Diseases ... Literature Review,” led by Dr. Hector O. Santos, examines the effect of coconut oil ...
(Date:12/5/2019)... (PRWEB) , ... December 05, 2019 , ... ... Practice M&A: Risks and Rewards of Building Platforms— on Thursday, December 12, 2019, ... competing for large, multi-specialty medical groups. Middle-market PE firms are scrambling to assemble ...
Breaking Medicine News(10 mins):